JP2019515884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515884A5 JP2019515884A5 JP2018549902A JP2018549902A JP2019515884A5 JP 2019515884 A5 JP2019515884 A5 JP 2019515884A5 JP 2018549902 A JP2018549902 A JP 2018549902A JP 2018549902 A JP2018549902 A JP 2018549902A JP 2019515884 A5 JP2019515884 A5 JP 2019515884A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- composition according
- day
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 239000003112 inhibitor Substances 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 claims 2
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 claims 1
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 claims 1
- 239000002139 L01XE22 - Masitinib Substances 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
- JACAAXNEHGBPOQ-LLVKDONJSA-N Talampanel Chemical compound C([C@H](N(N=1)C(C)=O)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 JACAAXNEHGBPOQ-LLVKDONJSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims 1
- 229960004755 ceftriaxone Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- 229960004655 masitinib Drugs 0.000 claims 1
- 230000002025 microglial effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229960004181 riluzole Drugs 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 229950004608 talampanel Drugs 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021204244A JP2022037132A (ja) | 2016-03-25 | 2021-12-16 | 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16162490 | 2016-03-25 | ||
| EP16162490.3 | 2016-03-25 | ||
| PCT/EP2017/057134 WO2017162884A1 (en) | 2016-03-25 | 2017-03-24 | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021204244A Division JP2022037132A (ja) | 2016-03-25 | 2021-12-16 | 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515884A JP2019515884A (ja) | 2019-06-13 |
| JP2019515884A5 true JP2019515884A5 (enExample) | 2020-03-12 |
| JP7250312B2 JP7250312B2 (ja) | 2023-04-03 |
Family
ID=55637258
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549902A Active JP7250312B2 (ja) | 2016-03-25 | 2017-03-24 | 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 |
| JP2021204244A Pending JP2022037132A (ja) | 2016-03-25 | 2021-12-16 | 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021204244A Pending JP2022037132A (ja) | 2016-03-25 | 2021-12-16 | 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10092564B2 (enExample) |
| EP (1) | EP3240538B1 (enExample) |
| JP (2) | JP7250312B2 (enExample) |
| KR (1) | KR102293847B1 (enExample) |
| CN (1) | CN108883108B (enExample) |
| AU (1) | AU2017236177B2 (enExample) |
| BR (1) | BR112018069515A2 (enExample) |
| CA (1) | CA3018635C (enExample) |
| DK (1) | DK3240538T3 (enExample) |
| EA (1) | EA038531B1 (enExample) |
| ES (1) | ES2899929T3 (enExample) |
| HU (1) | HUE057398T2 (enExample) |
| IL (1) | IL261856B (enExample) |
| MX (1) | MX390495B (enExample) |
| NZ (1) | NZ745778A (enExample) |
| PL (1) | PL3240538T3 (enExample) |
| PT (1) | PT3240538T (enExample) |
| SG (1) | SG11201808106YA (enExample) |
| SI (1) | SI3240538T1 (enExample) |
| WO (1) | WO2017162884A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| CN104869993B (zh) | 2012-10-25 | 2019-01-15 | 通用医疗公司 | 治疗阿尔茨海默病及相关疾病的组合疗法 |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| AU2014340182B2 (en) | 2013-10-22 | 2019-05-23 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| US20190240194A1 (en) * | 2016-08-31 | 2019-08-08 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
| MX379222B (es) | 2016-11-25 | 2025-03-10 | Genuv Inc | Composición para promover la diferenciación y protección de células madre neurales y método para inducir la regeneración neural usando las mismas. |
| CA3057040A1 (en) * | 2017-03-28 | 2018-10-04 | Novartis Ag | New methods for the treatment of multiple sclerosis |
| BR112019025346A2 (pt) * | 2017-05-30 | 2020-06-30 | Deciphera Pharmaceuticals, Inc. | uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin-3-il]-2-fluorofenil]-3-fenilureia e análogos para o tratamento de cânceres associados a anormalidades genéticas no receptor alfa do fator de crescimento derivado de plaquetas |
| US11692029B2 (en) | 2018-03-05 | 2023-07-04 | The Schepens Eye Research Institute, Inc. | Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors |
| KR20210071943A (ko) | 2018-07-02 | 2021-06-16 | 더 제너럴 하스피탈 코포레이션 | 크로몰린 소듐 및 α-락토스의 분말화된 제형 |
| US12383528B2 (en) | 2018-12-10 | 2025-08-12 | The General Hospital Corporation | Cromolyn esters and uses thereof |
| CN112618717A (zh) * | 2019-09-24 | 2021-04-09 | 北京大学深圳研究生院 | Btk抑制剂用于治疗肌萎缩侧索硬化症的用途 |
| FI4084779T3 (fi) * | 2019-12-30 | 2024-12-16 | Deciphera Pharmaceuticals Llc | 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia |
| WO2021207060A1 (en) | 2020-04-06 | 2021-10-14 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
| US12612391B2 (en) | 2020-12-28 | 2026-04-28 | The General Hospital Corporation | Cromolyn derivatives and uses thereof |
| US20250129067A1 (en) * | 2021-11-08 | 2025-04-24 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| WO2025113494A1 (zh) * | 2023-11-27 | 2025-06-05 | 浙江径科医药有限公司 | 多环类化合物及其应用 |
| WO2026015576A1 (en) * | 2024-07-09 | 2026-01-15 | PhenoNet, Inc. | Methods and systems for treatment of neurodegenerative disease and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW225528B (enExample) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| MXPA05001277A (es) | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| HRP20110709T1 (hr) | 2007-02-13 | 2011-11-30 | Ab Science | Postupak sinteze spojeva 2-aminotioazola kao inhibitora kinaza |
| TW201204360A (en) | 2010-04-20 | 2012-02-01 | Ab Science | Treatment of multiple sclerosis with MASITINIB |
| CN109316480A (zh) | 2011-07-13 | 2019-02-12 | 赛特凯恩蒂克公司 | 组合als疗法 |
| AU2013326463B2 (en) * | 2012-10-04 | 2018-01-18 | Ab Science | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
| EP2970317A4 (en) * | 2013-03-15 | 2016-11-02 | Dana Farber Cancer Inst Inc | PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES |
| US20160263110A1 (en) * | 2013-11-04 | 2016-09-15 | Ab Science | Use of masitinib for treatment of amyotrophic lateral sclerosis |
-
2017
- 2017-03-24 EA EA201800499A patent/EA038531B1/ru unknown
- 2017-03-24 MX MX2018011349A patent/MX390495B/es unknown
- 2017-03-24 DK DK17712175.3T patent/DK3240538T3/da active
- 2017-03-24 EP EP17712175.3A patent/EP3240538B1/en active Active
- 2017-03-24 US US15/545,800 patent/US10092564B2/en active Active
- 2017-03-24 KR KR1020187026871A patent/KR102293847B1/ko active Active
- 2017-03-24 WO PCT/EP2017/057134 patent/WO2017162884A1/en not_active Ceased
- 2017-03-24 HU HUE17712175A patent/HUE057398T2/hu unknown
- 2017-03-24 NZ NZ745778A patent/NZ745778A/en not_active IP Right Cessation
- 2017-03-24 PT PT177121753T patent/PT3240538T/pt unknown
- 2017-03-24 SI SI201730997T patent/SI3240538T1/sl unknown
- 2017-03-24 ES ES17712175T patent/ES2899929T3/es active Active
- 2017-03-24 AU AU2017236177A patent/AU2017236177B2/en active Active
- 2017-03-24 CN CN201780019760.9A patent/CN108883108B/zh active Active
- 2017-03-24 PL PL17712175T patent/PL3240538T3/pl unknown
- 2017-03-24 SG SG11201808106YA patent/SG11201808106YA/en unknown
- 2017-03-24 CA CA3018635A patent/CA3018635C/en active Active
- 2017-03-24 JP JP2018549902A patent/JP7250312B2/ja active Active
- 2017-03-24 BR BR112018069515A patent/BR112018069515A2/pt not_active Application Discontinuation
-
2018
- 2018-09-20 IL IL261856A patent/IL261856B/en unknown
-
2021
- 2021-12-16 JP JP2021204244A patent/JP2022037132A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101178318B1 (ko) | 효과적인 의약의 사용법 및 부작용 발현의 방어에 관한방법 | |
| JP2023002662A5 (enExample) | ||
| AU2018371177A1 (en) | Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases | |
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| SE9901573D0 (sv) | New compounds | |
| JP2019520344A5 (enExample) | ||
| TW202617156A (zh) | 用於治療進行性纖維化間質性肺病之新穎口服醫藥組合物及劑量療法 | |
| JPWO2023054732A5 (enExample) | ||
| RU2003100507A (ru) | Фармацевтические композиции | |
| JP2018517759A5 (enExample) | ||
| JP2019531286A5 (enExample) | ||
| JP2023531930A5 (enExample) | ||
| WO2004081012A1 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| WO2020067333A1 (ja) | 線維症治療用医薬組成物 | |
| MY160429A (en) | 2, 5-disubstituted 3-mercaptopentanoic acid | |
| HU222888B1 (hu) | Anilid vegyületek alkalmazása I típusú allergiás betegségek megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására | |
| SE9901572D0 (sv) | New compounds | |
| JP2022518288A5 (enExample) | ||
| HUP0203790A2 (hu) | (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére | |
| WO2019004465A1 (ja) | ペマフィブラートを含有する医薬 | |
| CA2240278A1 (en) | Malignant tumor metastasis inhibitors | |
| JP2023518430A (ja) | 感染症の治療におけるブシラミンの使用 | |
| WO2006041120A1 (ja) | 医薬組成物 | |
| WO2006046528A1 (ja) | 糸球体疾患治療剤 | |
| WO2024010030A1 (ja) | 血中マイオスタチン低下剤 |